Hapvida Participações e Investimentos

Rising Claims And Costly Integrations Will Hinder Brazil's Healthcare Delivery

AnalystLowTarget

Not Invested

Community Contributor

Published

03 Jul 25

Updated

12 Dec 25

Views

n/a

AnalystLowTarget's Fair Value

n/a

-57.7%

7.1%

-57.7%

7.1%

You can edit this narrative until Dec 13 5:05 AM. Then, changes will post as Updates.

Author's Valuation

R$2131.1% undervalued

AnalystLowTarget Fair Value

Narrative

Updates1

Shared on 12 Dec 25

Fair value Decreased 34%

HAPV3 Will Offer Upside As Earnings Multiple Remains Supportive

Analysts have reduced their 12 month price target for Hapvida Participações e Investimentos from R$31.85 to R$21.00. This reflects more conservative assumptions on discount rates, revenue growth and profit margins, while still expecting the stock to trade on a relatively supportive forward price to earnings multiple.

AnalystLowTarget Fair Value

R$21

31.1% undervalued

Future estimation in

Growth p.a.

Decrease

Increase

Current revenue growth rate

6.33%

Healthcare Services revenue growth rate

0.23%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

20.95%

Calculation

R$1.39b

Earnings '28

13.44x

PE Ratio '28

R$18.68b

Market Cap '28

R$18.68b

Market Cap '28

496.53m

No. shares '28

R$37.63

Share Price '28

R$37.63 Share Price '28

Discounted to 2025 @ 21.51% p.a.

R$20.98

Fair Value '25